1-20 of 888 Search Results for

international reference prices

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Article
J Health Polit Policy Law (2022) 47 (6): 779–796.
Published: 01 December 2022
...Richard Frank; Rena M. Conti; Jonathan Gruber Abstract International reference prices (IRP), also called external reference prices, are widely used across developed nations. IRP uses the prices paid in other countries to either inform negotiations with the pharmaceutical industry or as a cap...
Journal Article
J Health Polit Policy Law (2021) 46 (6): 1053–1068.
Published: 01 December 2021
..., the Trump administration failed to implement any of their more ambitious reform ideas. This article considers three of the Trump administration's signature policies—state-sponsored prescription drug importation, Medicare Part B international reference pricing, and reforms to the Medicare Part D rebate...
Journal Article
J Health Polit Policy Law (2014) 39 (3): 691–705.
Published: 01 June 2014
... the Netherlands shows that prices decreased by up to 93 percent for high-volume products after the introduction of tendering (Kanavos, Seeley, and Vandoros 2009 ). Neither internal reference pricing at the molecule level nor price caps would bring the needed generic price cuts in Russia. However, Russia...
FIGURES
Journal Article
J Health Polit Policy Law (2021) 46 (4): 599–609.
Published: 01 August 2021
... of an independent review board to recommend reasonable prices for new specialty drugs lacking competition in the US market will also be an important measure to lower US drug prices, yet its proposed use of international reference pricing may be more difficult to implement than expected (Gavulic, Pelletier-Fleury...
Journal Article
J Health Polit Policy Law (2022) 47 (6): 709–729.
Published: 01 December 2022
... and international reference pricing (Ferrario et al. 2020 ). An examination of income and wealth inequalities and other social determinants that shape unequal pharmacotherapy access reinforces that medication disparities are inextricable from broader racial inequities in the United States. For example...
FIGURES
Journal Article
J Health Polit Policy Law (2022) 47 (6): 755–778.
Published: 01 December 2022
... and Martikainen 2015 ). In Europe, however, international reference pricing is part of a broader strategy, not the sole criterion—and for good reason. International comparison helps reduce price discrimination among European nations; it does not ensure reasonable prices, because prices still reflect...
FIGURES
Journal Article
J Health Polit Policy Law (2022) 47 (1): 63–92.
Published: 01 February 2022
... ). (The problem with international reference prices, whether in Europe or South America, is that the real prices governments and purchasers pay after rebates remain opaque.) In 2015 UNASUR also coordinated with Mercosur to negotiate and jointly procure eight single-source high-cost medicines in the region...
FIGURES
Journal Article
J Health Polit Policy Law (2008) 33 (5): 979–1005.
Published: 01 October 2008
...- ing to health care financing reforms was passed; these are listed in table 1. The scope of the individual laws vary from comprehensive, as in the case of the Healthcare Structure Act (1993) and the SHI Modernization Act (2003), to specific, as reflected by the Reference Price Adjustment Act...
Journal Article
J Health Polit Policy Law (2013) 38 (3): 573–597.
Published: 01 June 2013
... . www.leem.org/article/chiffre-daffaires (accessed December 23, 2012). López-Casasnovas G. Puig-Junoy J. . 2000 . “Review of the Literature on Reference Pricing.” Health Policy 54 , no. 2 : 87 – 123 . Medicines and Healthcare Products Regulatory Agency (MHRA) . 2003 . “Changing...
Journal Article
J Health Polit Policy Law (1998) 23 (2): 265–290.
Published: 01 April 1998
... corporations for worldwide distribu- tion. What remains unclear are the international effects associated with orphan drug policies—in particular, the effect of the U.S. Orphan Drug Act outside the United States. The unregulated market determination of orphan drug prices in the United States, combined...
Journal Article
J Health Polit Policy Law (2011) 36 (4): 775–790.
Published: 01 August 2011
... costs (Wayne and Armstrong 2009; Armstrong and Wayne 2009b; Wayne and Epstein 2010). Evidence from Other Perspectives The relative importance of price and volume looks quite different if one considers investigations of cost control from other perspectives.4 Most obvious are the international...
Journal Article
J Health Polit Policy Law (2011) 36 (4): 771–774.
Published: 01 August 2011
...Harold A. Pollack © 2011 by Duke University Press 2011 References Marmor T. Oberlander J. White J. . 2009 . The Obama Administration's Options for Health Care Cost Control: Hope Versus Reality . Annals of Internal Medicine 150 ( 7 ): 485 – 489 . Social...
Journal Article
J Health Polit Policy Law (2008) 33 (2): 319–324.
Published: 01 April 2008
... -111. Waltham, MA: PAREXEL International. Public Citizen. 2001 . Rx R&D Myths: The Case Against the Drug Industry's R&D Scare Card . July 23. www.citizen.org/documents/rdmyths.pdf . Scherer, F. M., 1993 . Pricing, Profits, and Technological Progress in the Pharmaceutical Industry...
Journal Article
J Health Polit Policy Law (1999) 24 (5): 1191–1200.
Published: 01 October 1999
...David M. Frankford Copyright © 1999 by Duke University Press 1999 References Breyer , S. G. 1982 . Regulation and Its Reform. Cambridge: Harvard University Press. Frankford , D. M. 1996 . Food Allergy and the Health Care Financing Administration: A Story of Rage. Widener...
Journal Article
J Health Polit Policy Law (2011) 36 (2): 295–316.
Published: 01 April 2011
... of Biopharmaceuticals: An International Comparison . Health Affairs 25 : 1353 – 1362 . ———. 2008 . International Prices and Availability of Pharmaceuticals in 2005 . Health Affairs 27 : 221 – 233 . Danzon P. Wang Y. R. Wang L. . 2005 . The Impact of Price Regulation on the Launch...
Journal Article
J Health Polit Policy Law (1988) 13 (2): 263–278.
Published: 01 April 1988
... innovations. Whether expenditures and price indices will continue to increase at historic rates will thus depend on whether consumers, acting either individually or collectively, are willing to pay for the bulk of the innovations. Based on HMO and international experience, there is reason to think...
Journal Article
J Health Polit Policy Law (2013) 38 (6): 1081–1102.
Published: 01 December 2013
... to rectify. Some countries, such as the Netherlands, had a therapeutic reference price system, where similar drugs are “clustered” and reimbursed at the same level. When economic evaluation was introduced in the Netherlands, it was used to help set a price for drugs that could not be placed...
FIGURES
Journal Article
J Health Polit Policy Law (1999) 24 (4): 653–696.
Published: 01 August 1999
... on appropriateness of care is to impose a capacity constraint, the technocratic pursuit of appropriateness normally refers to less blunt measures, making appropriateness a separate theory. 3. Among other statements of the price/volume (or price/quantity) distinction, see Barer, Lomas, and Sanmartin 1996. 660...
Journal Article
J Health Polit Policy Law (2007) 32 (5): 895–913.
Published: 01 October 2007
... rhetoric that all new drugs are thera- peutically better than old ones, when five-sixths of them are not (National Institute for Health Care Management Research and Education Founda- tion 2002; Prescrire International 2004). Equally misleading is using the label “new” to claim that if prices...
Journal Article
J Health Polit Policy Law (2022) 47 (6): 621–628.
Published: 01 December 2022
..., and Sachs 2021 ; Padula 2019 ). The case for reform is compelling. The United States spends more on prescription drugs than any of our international peers, reflecting the absence of systemwide controls on prices. In 2018, drug prices in the United States were 256% of the prices in other Organization...